soul trial oral semaglutide cardiovascular outcomes trial results π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Oral Semaglutide's Impact on Cardiovascular
Pay in 4 interest-free payments of $7.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6















.webp)












